Combined Immune Checkpoint Blockade and Stereotactic Ablative Radiotherapy Can Stimulate Response to Immunotherapy in Metastatic Melanoma: A Case Report.

Combined Immune Checkpoint Blockade and Stereotactic Ablative Radiotherapy Can Stimulate Response to Immunotherapy in Metastatic Melanoma: A Case Report.

Publication date: Feb 08, 2019

Skin cancer is the most commonly diagnosed malignancy in the United States, and invasive cutaneous melanoma is responsible for the vast majority of skin cancer-related deaths. Treatment options for patients with regional nodal disease, in-transit metastases, or locally advanced or distant metastatic disease are challenging. Historically survival rates in this patient population are dismal. Improved systemic control is possible using targeted agents and checkpoint inhibitors have redefined treatment outcomes. Furthermore, multi-modal therapy incorporating radiation may improve survival outcomes by priming the immune system for antigen release and help in reversing T-cell exhaustion. Herein, we describe a patient with widespread metastatic melanoma with progressive systemic disease while receiving checkpoint inhibition therapy that was reversed after combined immunoradiotherapy. The patient is now more than 41 months from diagnosis with durable, stable systemic disease.

Open Access PDF

Moran, A., Azghadi, S., Maverakis, E.M., Christensen, S., and Dyer, B.A. Combined Immune Checkpoint Blockade and Stereotactic Ablative Radiotherapy Can Stimulate Response to Immunotherapy in Metastatic Melanoma: A Case Report. 23029. 2019 Cureus (11):2.

Concepts Keywords
Antigen Skin cancer
Immune System Stereotactic surgery
Immunotherapy Immunotherapy
Malignancy Metastasis
Melanoma Radiation
Metastases Radiation therapy
Metastatic Melanoma
Modal Cancer treatments
Priming RTT
Progressive Health
Radiation Clinical medicine
Radiotherapy Medicine
Skin Cancer Immunoradiotherapy
Systemic Disease Immunotherapy
T Cell Radiation therapy
Transit Regional nodal disease
United States Widespread metastatic melanoma
Invasive cutaneous melanoma
Abscopal immunotherapy melanoma
Majority skin cancer
Transit metastases

Semantics

Type Source Name
gene UNIPROT PDCD1
gene UNIPROT RPL17
disease MESH diagnosis
pathway BSID Release
pathway BSID Immune System
drug DRUGBANK Sulpiride
disease MESH multi
disease MESH metastases
gene UNIPROT NODAL
disease DOID cutaneous melanoma
disease MESH malignancy
disease DOID Skin cancer
disease MESH Skin cancer
pathway BSID Melanoma
disease DOID Melanoma
disease MESH Melanoma

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *